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Summary
Expression of the cyclin-dependent kinase inhibitor p27Kip1 (p27) is frequently reduced in human colorectal cancer, and
this correlates with poor patient prognosis. To clarify the role of p27 in gastrointestinal (GI) cancer, we measured p27
expression, as well as the effect of germline deletion of p27, in 3 different mouse models of GI neoplasia. p27 expression
was frequently reduced in GI tumors arising in 1,2-dimethylhydrazine (DMH) treated mice, and in Apc mutant Min/ mice,
but not in GI tumors arising in Smad3 mutant mice. Germline deletion of p27 resulted in accelerated tumor development
and increased tumor cell proliferation in both DMH treated and Min/ mice, but not in Smad3 mutant mice. p27 deficiency
also led to increased adenoma to adenocarcinoma progression. These results indicate that reduction of p27 cooperates
with mutations in Apc but not in Smad3 during GI tumorigenesis. Thus, tumor suppression by p27 is contingent on the
specific oncogenic pathway that drives tumor development.
Introduction differentiation (Mori et al., 1997; Yasui et al., 1997; Kim et al.,
2000; Singh et al., 1998). With regard to colon cancer, the me-
p27Kip1 belongs to the Cip/Kip family of cyclin-dependent kinase dian five-year survival rates for patients with colorectal cancer
(Cdk) inhibitors that includes p21Cip1 and p57Kip2 (Sherr and Rob- are dramatically reduced if tumors have low versus high p27
erts, 1999). The Cdk inhibitors bind to cyclin/Cdk complexes, expression (Loda et al., 1997). Other studies have linked low
block the activation of Cdks, and inhibit cell cycle progression. p27 expression to more advanced colon cancer stage and to
p27 inhibits most cyclin/Cdk complexes, although it is most more poorly differentiated tumors (Ciaparrone et al., 1998;
prominently linked to inhibition of cyclinE/Cdk2 (Polyak et al., Sgambato et al., 1999). In matched pairs of primary and meta-
1994b). Endogenous expression of p27 in cell lines causes cell static colorectal tumors, metastatic cells showed reduced p27
cycle arrest in G1 (Polyak et al., 1994b; Toyoshima and Hunter, expression relative to the primary tumor (Thomas et al., 1998).
1994). Mitogen withdrawal, treatment of cells with TGF-, or Point mutations in the coding region of the p27 gene
cadherin-mediated cell-cell contact lead to increased p27 bind- (CDKN1B) are rare in human tumors (Ponce-Castaneda et al.,
ing to cyclinE/Cdk2 and cyclinA/Cdk2 complexes, and inhibition 1995; Kawamata et al., 1995; Pietenpol et al., 1995), although
of G1/S progression (Polyak et al., 1994a; St. Croix et al., 1998; loss of heterozygosity (LOH) is observed in some tumor types
Levenberg et al., 1999). (Stegmaier et al., 1995; Pietenpol et al., 1995; Hatta et al., 1997).
The role of p27 in cancer is poorly defined. Reduced p27 The lack of tumor-associated mutations in CDKN1B has hin-
expression is an unfavorable prognostic marker in many human dered efforts to establish a causal role of p27 in tumor progres-
cancers, including tumors of the colon, stomach, breast, lung, sion. However, experiments in p27 deficient mice have estab-
prostate, and ovary (Lloyd et al., 1999; Philipp-Staheli et al., lished p27 as a haploinsufficient tumor suppressor. p27 null
2001). Loss of p27 in tumors is also correlated with tumor ag- (/) mice are predisposed to spontaneous pituitary adenomas
(Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996),gressiveness, depth of tumor cell invasion, and poor state of
S I G N I F I C A N C E
The role of p27 in GI cancer is poorly understood, particularly the association of reduced p27 expression with poor clinical outcome.
Our findings demonstrate a causal connection between reduction of p27 in GI tumors and increased proliferation, tumor growth,
and tumor-associated mortality. Colon tumors from p27 deficient mice also showed more aggressive phenotypes, including complete
invasion into the serosal space and lymphatic vessel penetration. This suggests a role for p27 in the early stages of metastasis, a
finding that could have clinical implications. Furthermore, tumor suppression by p27 is not universal, but depends on the primary
genetic lesion fueling tumor growth. This suggests that further stratification of human tumors according to defined molecular alterations,
in combination with p27 staining, may improve prognostic sensitivity.
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as well as radiation- and ENU-induced tumors in multiple epithe-
lial tissues, with colon adenomas and adenocarcinomas being
a prominent tumor type (Fero et al., 1998). p27 heterozygous
mice (/) show an intermediate susceptibility to the same
tumor types.
Our first aim in the present study was to address the cellular
mechanism by which p27 suppresses colon tumorigenesis. We
treated wild-type and p27 knockout mice with the carcinogen
1,2-dimethylhydrazine (DMH), an alkylating agent that induces
adenomas and adenocarcinomas specifically in the colon. These
tumors closely parallel human colonic neoplasia in clinical and
pathological features (Ahnen, 1985; LaMont and O’Gorman,
1978). In wild-type mice, p27 protein expression was reduced in
a subset of DMH-induced colon tumors. Both p27/ and/
mice showed accelerated colon tumor development, increased
tumor cell proliferation, and enhanced adenoma to adenocarci-
noma progression, indicating a prominent tumor suppressing
function of p27 in colonic neoplasia.
Our second aim was to determine if p27 deficiency cooper-
ates with mutations in two central oncogenic pathways during
GI neoplasia: the Wnt/Apc and TGF-/Smad3 pathways. The
APC protein is part of the Wnt signaling pathway, and mutation
of the APC gene plays a key role early in the development of
both human and murine intestinal neoplasia. Individuals with
familial adenomatous polyposis bear a germline mutation in
APC and are highly predisposed to colorectal cancer (Groden
et al., 1991; Nishisho et al., 1991), and somatic mutations in
APC are found in the majority of sporadic human colorectal
tumors (Fearon and Vogelstein, 1990; Polakis, 1997). Likewise,
mice bearing a germline mutation in Apc, e.g., Min/ mice, are
highly prone to intestinal neoplasia (Su et al., 1992).
The TGF- pathway is also frequently altered in colorectal
cancer (Akhurst and Derynck, 2001). Many colorectal cancer
cells are resistant to growth inhibition by TGF-, due to muta-
tions in members of the TGF/SMAD signaling pathway (Mar-
kowitz et al., 1995; Miyaki et al., 1999). SMAD3 is one of several
intracellular signaling proteins that mediate the inhibition of epi-
thelial cell proliferation by TGF- (Zhou et al., 1999). Mice with
a targeted disruption in Smad3 or TGF-1 develop colorectal
Figure 1. p27 reduction decreases tumor-free survival of DMH-treated andadenocarcinomas (Zhu et al., 1998; Engle et al., 1999), indicating
Min/ mice but not Smad3/ mice
an important role for TGF- signaling in both human and murine
A: Survival of DMH-treated mice is significantly decreased with reduction
GI neoplasia. of p27 gene dosage (log rank test: wt versus p27/ p  0.0001, p27/
versus p27/ p  0.0001, wt versus p27/ p  0.2759). The insert showsTo clarify the role of p27 in both the Wnt/Apc and TGF-/
that p27 reduction leads to a higher percentage of adenocarcinomas.Smad signaling pathways during GI tumor development, we
Due to different age at sacrifice, this likely underestimates the frequencygenerated p27/Apc and p27/Smad3 compound mutant mice. for p27 deficient mice. B: Survival rate of Min/ mice is decreased with p27
Germline deletion of p27 markedly accelerated the rate of devel- reduction (log rank test: wt versus p27/ p 0.005, wt versus p27/
p 0.001. C: Survival curves for Smad3 null mice show no difference be-opment of intestinal tumors bearing mutations in Apc, but had
tween Smad3/p27/ and Smad3/p27/ mice (log rank test: p no measurable effect in tumors bearing mutations in Smad3.
0.4). The insert shows similar tumor multiplicities between the two p27 geno-
types (2-sample t test: p  0.10).
Results
p27 deficiency reduces latency and increases
malignancy of chemically induced colorectal tumors littermate controls (Figure 1A). The primary cause of morbidity
To specifically address the role of p27 in colorectal cancer, was intestinal obstruction and rectal prolapse as a result of
cohorts of p27/, p27/, and wild-type littermates were tumors of the colon and rectal region. Other tumor types also
treated with DMH and sacrificed when moribund. Overall tumor- reduced survival in p27-deficient mice, including uterine tumors
free survival was significantly reduced in p27/ mice, and to of several histologic subtypes and pituitary adenomas (data
not shown). Survival plots of the subset of animals that werean intermediate extent in p27/ mice, relative to wild-type
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Figure 2. Colon tumors from p27 deficient mice demonstrate more aggressive features
Shown are H&E stained sections of colon tumors from DMH treated p27/ mice on the left with the corresponding high-power views (indicated by box)
on the right. A: A morphologically complex neoplasm demonstrating an adenocarcinomatous change with invasion into the submucosa and muscularis
(m). These changes exist adjacent to areas of focal hyperplasia (h). Lymphoid cell aggregates (ly) are also present in scattered locations. B: Dysplastic
cells, abundant mitotic figures, and infiltrating immune cells within the tumor are shown. C: A large colonic neoplasm with focal invasion of the submucosa
(m), shown in D. E: A highly malignant diffusely distributed adenocarcinoma with tubular and scirrhous properties extends throughout the submucosa and
serosa. A raft of neoplastic cells is present within a serosal lymphatic vessel (lv) (F).
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sacrificed only due to complications from colorectal tumors
were similar to Figure 1A, and showed that p27 deficiency spe-
cifically accelerated colon tumor development and associated
mortality, and did so in a p27 gene dosage-dependent manner.
Colorectal tumors from p27/ (n  15), p27/ (n  24),
and p27/ (n 10) littermates were evaluated for histopatho-
logic features. The majority of tumors from wild-type mice were
classified as adenomas, whereas the incidence of colorectal
adenocarcinomas, as well as the ratio of adenocarcinomas to
adenomas, were both significantly increased in p27 deficient
mice (Figure 1A, insert). In addition to increased carcinoma in
situ, a number of adenocarcinomas from p27 / and p27/
mice showed clear evidence of invasion through the submucosa
and muscularis propria into the serosal space (Figures 2A–2D).
In more severe cases, lymphatic vessel invasion by tumor cells
was observed (Figures 2E and 2F). Thus, germline reduction of
p27 decreased the latency for DMH-induced colorectal tumor
development and resulted in more aggressive tumor behavior.
Individual DMH-induced tumors are likely to harbor different
combinations of mutations in k-ras (Jacoby et al., 1991),
-catenin (Blum et al., 2001), Apc, or other oncogenes or tumor
suppressor genes. This genetic diversity between tumors is
likely to closely mirror human colorectal neoplasia, but it also
prohibits the analysis of the tumor-suppressing role of p27 in
a defined genetic setting or molecular pathway. In addition, the
use of chemical or physical agents in tumor induction could
have other nongenotoxic effects that influence p27 levels or
other pathways. To determine the effect of p27 levels on GI
tumor development in the absence of exogenous agents, as
well as to determine if tumor suppression by p27 depends on
the genetic makeup of the tumor, we used defined genetic Figure 3. Reduction of p27 increases tumor multiplicity in Min/ mice
models of GI neoplasia. A: Tumor multiplicity throughout the GI tract is increased in Min/p27/
mice and Min//p27/ as compared to Min/p27/ mice. Vertical
bars represent t-based 95% confidence intervals. p27/ versus p27/Reduction of p27 accelerates tumor growth
at 9 weeks p  0.002, p27/ versus p27/ at 13 weeks p  0.07 usingand decreases survival of Min/ mice the two sample t-test. B: Reduction of p27 has the largest relative effect
Multiple intestinal neoplasia (Min/) mice bear a heterozygous on tumor number in the proximal region of the small intestine (white p27/,
mutation in the Apc gene, and these mice spontaneously de- gray p27/, black p27/). D, distal; M, middle; P, proximal.
velop numerous adenomas in both the small intestine and colon
(Su et al., 1992; Shoemaker et al., 1997). Min/ mice were
crossed to p27-deficient mice, and spontaneous tumor devel-
Importantly, p27/ mice with two wild-type copies of Apc didopment was compared between the single and compound mu-
not develop GI tumors up to one year of age. These resultstant animals. Min/ mice developed symptoms of tumor bur-
demonstrate a potent synergistic interaction between reductionden, including anemia and lethargy, starting at 16 weeks of
of p27 and mutation in Apc during GI neoplasia.age, whereas Min/ p27/ mice became moribund earlier,
Intestinal neoplasms from Min/mice had morphologic fea-between 12–14 weeks of age, and Min/ p27/ mice had an
tures ranging from adenomatous hyperplasia to (most com-even shorter latency, succumbing by around 9 weeks of age
monly) adenoma, with no difference in tumor histology noted(Figure 1B). Morbidity in all genotypes was due to extensive
between p27 genotypes (Figure 4A). However, the very earlytumor development throughout the small intestine and colon.
lethality of p27 deficient mice in this study (9–10 weeks of age)Both Min/p27/ and Min/p27/ mice carried a greater
tumor burden throughout the GI tract relative to Min/ mice might well preclude detection of an effect of p27 on malignant
(Figures 3A and 3B). For example, 9-week-old Min/ p27/, progression.
Min/ p27/, and Min/ mice had an average ( standard
deviation) of 101 (49), 35 (13), and 21 (9.6) tumors per Reduction of p27 does not enhance tumor development
in Smad3 mutant micemouse, respectively. Reduction of p27 also resulted in increased
tumor size (Figures 4A–4C). Of colon tumors from Min/ To address whether intestinal tumor suppression by p27 is a
general phenomenon or if it is specific to the oncogenic pathwayp27/ mice, 42% (5/12) were  3 mm in size by 9 weeks of
age compared to 0/6 in Min/ mice. Of small intestinal tumors driving tumor development, we next examined Smad3/
knockout mice. Smad3/ mice are defective in the TGF-from Min/ p27/ mice, 29% (115/393) were  2 mm in size
by 9 weeks of age, compared to 0/100 in Min/ mice. Tumor signaling pathway, and spontaneously develop intestinal adeno-
carcinomas (Zhu et al., 1998). p27 deficient mice were crossedmultiplicity and size in Min/ p27/ mice was also signifi-
cantly increased compared to Min/ mice (Figures 4B–4C). to Smad3 deficient mice to generate compound mutant animals.
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Figure 4. Reduction of p27 leads to larger tumor
size and increased proliferative index in Min/
mice and DMH-treated mice
A: Adenomas in the small intestine of Min/
p27/ mice (top) are larger and more nu-
merous than in Min/p27/ mice (bottom) at
nine weeks of age. Arrows point to tumors. H&E
stained sections of typical adenomas from Min/
p27/ (upper right) and Min/ mice (lower
right) are shown. The percentage of large size
class tumors per mouse in colon (B) and small
intestine (C) is significantly greater in p27 defi-
cient mice. Vertical bars represent t-based 95%
confidence intervals. p-values are: colon: p 
0.11 for p27/ versus wt at 9 weeks, p  0.09
for p27/ versus wt at 13 weeks; small intestine:
p  0.001 for p27/ versus wt at 9 weeks, p 
0.02 for p27/ versus wt at 13 weeks. Mitotic
(D) and BrdU (E) labeling indices are higher in
adenomas from Min/ p27/ and Min/
p27/ mice relative to Min/ mice (white
p27/, gray p27/, black p27/). Values
are the mean  standard deviation. The differ-
ence between the mitotic indices of adenomas
from Min/ mice and Min/p27/ mice was
highly significant in all sections of the small intes-
tine but not in the colon. For Min/p27/ versus
Min/p27/ mice, p  0.07 (distal), 0.18 (mid-
dle), 0.01 (proximal); for Min/p27/ versus
Min/p27/ mice, p  0.002 (distal), 0.001
(middle), 0.001 (proximal) (Wilcoxon rank sum
test). The following total number of powerfields
was counted per p27 genotype: for mitotic in-
dex, 83 (wt), 110 (p27/), 55 (p27/); for BrdU
index, 90 (wt), 84 (p27/), 40 (p27/) in tu-
mors; the following number of crypts was
counted for normal tissue: 365 (wt), 478
(p27/), 452 (p27/). F: The mitotic index
within colon adenomas from DMH treated mice
is also significantly higher in mice with reduced
p27 (Wilcoxon rank sum test: wt versus p27/
p 0.0327, p27/ versus p27/p 0.3951, wt
versus p27/ p  0.0316). Mitotic figures were
counted in H&E stained sections of colon adeno-
mas (G).
Smad3/ p27/ offspring were generated in fewer than Smad3/ and Smad3/ p27/ mice (Figure 1C). There
was also no significant difference in tumor multiplicity (Figureexpected numbers and died at around 4 weeks of age prior
to colorectal tumor development, indicating a nontumorigenic 1C, insert) or in tumor size (data not shown) between p27 geno-
types. Cecal and colon tumors arising in Smad3/ andinteraction between Smad3 and p27. These results will be de-
scribed elsewhere. Smad3/ and Smad3/ p27/ lit- Smad3/p27/mice were classified as both adenomas and
adenocarcinomas, with no difference in histological subtypestermates were sacrificed when moribund, between 15–30 weeks
of age. The primary cause of morbidity was anemia due to noted between groups. Enlarged lymph nodes were frequently
observed in tumor bearing mice, but we did not observe meta-bleeding of large tumors within the cecum or colon, and rectal
prolapse. However, in contrast to the two previous studies, there static cells in any of the lymph nodes (n  27), or other major
organ sites examined.was no measurable difference in tumor-free survival between
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Figure 6. Reduced p27 expression in DMH-
induced and Min/ colon adenomas but not in
Smad3/ adenomas
A: Western blot analysis of nuclear (n) and cyto-
plasmic (c) extracts from colon adenomas of
DMH-treated mice was performed using an anti-
p27 polyclonal antibody. Normal colon tissues
were from age-matched wild-type C57BL6 mice.
The Sin3A blot confirms complete cellular frac-
tionation as well as equal loading for nuclear
extracts. Ponceau S staining was used in all West-
ern blots to confirm equal loading. B: Skp2 (p45)
protein levels are increased in DMH-induced co-
lon tumors, but do not correlate with p27 levels.
Antibodies against nuclear proteins Sin3A and
Max were used to confirm complete cellular
fractionation. No contamination of cytoplasmic
fractions by nuclear proteins was detected (see
Figure 6A and data not shown). C: Western blot
analysis of nuclear extracts shows reduced ex-
pression of p27 protein in Min/ adenomas but
abundant expression in Smad3/ adenomas
compared to normal colon or normal colonic
crypt epithelial cell extracts. Cyclin D1 levels are
increased in colon tumors but are not differen-
tially regulated in Min/ versus Smad3/mice.
p45 is more abundant in normal colonic crypt
cells than in total colon tissue, and is strongly
increased in a subset of Min/ adenoma sam-
ples. D: Densitometric measurement of Western
blots with 21 DMH-induced colon tumors and 8
normal colon samples was performed to derive
nuclear/cytoplasmic ratios. 12 adenomas and 8
normal colon samples from Min/ mice were
used to derive densitometric measurements for
nuclear p27 levels. Note reduced levels of nu-
clear p27 in a subset of DMH induced tumors
and reduced nuclear levels of p27 in Min/ ade-
nomas.
Nuclear p27 is reduced in adenomas and mice, we next determined whether p27 protein expression was
altered in tumors arising in p27 wild-type mice from these sameadenocarcinomas from DMH-treated and Min/
mice, but not Smad3/ mice three models. Normal intestinal epithelial cells showed diffuse
nuclear and cytoplasmic staining for p27. Very intense nuclearGiven the significant effect of p27-deficiency on GI tumor devel-
opment in DMH-treated and Min/ mice, but not Smad3/ p27 staining was seen in the occasional cell within the crypt,
Figure 5. p27 and -catenin expression patterns in colon tumors
A and E: Section of a colon adenoma from DMH treated mouse probed with p27 or -catenin antibody, respectively. Note decreased nuclear staining
for p27 with some remaining cytoplasmic staining, and nuclear and cytoplasmic staining for -catenin within tumor cells. B and F: Colon adenoma from
a Min/ mouse. Note overall reduction of p27 staining along with prominent nuclear -catenin staining. C and G: Colon adenoma from a Smad3/
mouse. Note strong nuclear staining for p27 throughout section along with weaker cytoplasmic staining. -catenin staining is exclusively cytoplasmic. D:
Normal colonic mucosa stained for p27. Note strong nuclear staining scattered throughout bottom third of crypts and weaker overall cytoplasmic staining.
Arrows: p27 positive nuclei; arrow heads: p27 negative nuclei.
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and colon (Figures 6C and 6D). In marked contrast, p27 levels
remained high in tumor lysates from Smad3/ mice, similar
to that seen in normal intestinal tissue (Figure 6C), confirming
the immunostaining results (Figures 5A–5C). Thus, reduction of
nuclear p27 protein is seen in a subset of intestinal and colonic
adenomas and adenocarcinomas from DMH treated and Min/
mice, but not in Smad3 mutant mice.
These findings, together with the genetic results described
above, indicate that reduced p27 expression that is observed
in intestinal tumor cells is not coincidental but rather is causally
related to increased tumor growth. In tumors that show reduced
p27 expression, e.g., in the DMH-treated and Min/mice, germ-
line reduction of p27 leads to increased tumor growth, whereas
tumors from Smad3/ mice do not show reduction of p27
expression and deletion of p27 has no measurable effect on
tumor development. Thus, the selective pressure for reducing
p27 expression varies depending on the predominant genetic
lesion driving tumor development.
p27-deficiency enhances proliferation in GI tumors
from DMH-treated and Min/ mice
Figure 7. LOH analysis of p27 (Cdkn1b) and Apc in GI tumors
The earlier appearance of GI tumors in p27-deficient mice in
A: Semiquantitative PCR amplification using p27 specific primers reveals no
the DMH and Min study, and the known function of p27 as anLOH of wild-type p27 allele in colon tumors from p27/ mice. B: The wild-
inhibitor of cell cycle progression, suggested that one mecha-type Apc allele is lost in intestinal tumors from Min/ mice independent of
p27 genotype. Representative results of a PCR analysis using Apc specific nism of tumor suppression by p27 may be to regulate tumor
primers are shown. (T  tumor, N  normal tissue). cell proliferation. Indeed, the mitotic index in adenomas from
p27/ and p27/ mice was 2- to 3-fold greater than the
mitotic index in adenomas from wild-type mice (Figures 4D–4G).
This effect of p27 on tumor cell proliferation was seen in both
generally 1–2 per crypt cross-section (Figure 5D). This pattern DMH-induced colon tumors and in small intestinal tumors from
of p27 staining differs from Ki-67 staining of proliferating cells, Min/ mice. BrdU labeling index of S-phase cells confirmed
which is localized at the bottom third of the crypt, and from these findings (Figure 4E). The apoptotic index in adenomas did
p21/Cip1 staining, which is localized to cells in the upper region not differ between p27 genotypes (data not shown). In contrast,
of the crypt (El-Deiry et al., 1995). The staining pattern for p27 crypt cells of normal intestinal tissue displayed similar mitotic
was similar in tumors from DMH-treated and Min/mice. Large and BrdU labeling indices between p27 genotypes (Figure 4E).
areas of most tumors showed noticeably reduced or undetect- These data indicate that p27 functions to retard intestinal and
able nuclear p27 staining (Figures 5A and 5B). Highly differenti- colonic adenoma growth by reducing tumor cell proliferation,
ated, glandular structures of the tumors tended to show more and it does so in a p27 gene dosage dependent manner.
prominent nuclear p27 staining, whereas pseudoglandular struc-
tures or more poorly differentiated areas lacked nuclear p27 Apc, but not p27, shows loss of heterozygosity
staining. p27 staining was present in mesenchymal cells within in tumors
the tumor, and prominent nuclear p27 staining was observed p27 heterozygous mice showed an intermediate effect with re-
in infiltrating lymphocytes. Overall, the distribution of p27 stain- spect to the phenotypes described above, including the timing
ing in normal colon tissue and tumor tissue from both DMH- of tumor-related mortality (Figures 1A and 1B), tumor cell prolif-
treated and Min/ mice bears close resemblance to staining eration (Figure 4), and tumor malignancy (Figure 1A). In contrast
seen in human tissue (Ciaparrone et al., 1998). In marked con- to Apc and other tumor suppressor genes that show LOH in
trast, most adenomas and adenocarcinomas from Smad3/ tumors, loss of the wild-type p27 allele has not been observed
mice displayed strong nuclear p27 staining within most cells of in tumors from p27 heterozygous mice (Fero et al., 1998). To
the tumor (Figure 5C). confirm this in the current study, we tested for LOH of p27 by
Western blot analysis confirmed these histologic findings. semiquantitative PCR. This analysis showed that 13 out of 13
In normal colon tissue, abundant p27 was detected in both DMH-induced tumors from p27/ mice and ten out of ten
nuclear and cytoplasmic fractions (Figure 6A). Approximately tumors from Min/p27/ retained the wild-type p27 allele
one-third of DMH-induced colon adenomas and adenocarcino- (Figure 7A and data not shown). In both studies, Western blot
mas showed markedly reduced levels of nuclear p27, but re- analysis of tumor extracts of p27/ mice showed that p27
tained abundant cytoplasmic p27. Representative tumor sam- protein expression was retained, but at reduced levels com-
ples are shown in Figure 6A. Densitometric analysis confirmed pared to wild-type, in all tumors examined (data not shown).
that, on average, these tumors had reduced nuclear/cyto- Thus, p27 suppresses intestinal adenoma and colon adenocar-
plasmic ratios of p27 relative to normal colon tissue (Figure 6D). cinoma development in a quantitative manner.
The majority of tumors in both the small intestine and colon Close to 100% of adenomas from Min/ mice show com-
from Min/ mice also showed reduced levels of p27 in both the plete loss of the wild-type Apc allele, usually via chromosomal
nondisjunction (Luongo et al., 1994). A possible mechanism fornuclear and cytoplasmic fractions compared to normal intestine
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synergy between p27 and Apc is that reduction of p27 might between levels of p27 and Skp2, as tumors with low or high
p27 both showed similar high levels of Skp2. Skp2 expressionobviate the need for homozygous inactivation of Apc, thereby
accelerating tumor development. However, all adenomas analyzed was slightly increased in adenomas from both Min/ and
Smad3/mice, with several Min/ tumors showing abundantfrom Min/ (n 7), Min/ p27/ (n 10), and Min/p27/
(n  6) mice showed loss of the wild-type Apc allele (Figure Skp2 (Figure 6C). Here again, there was no clear correlation
between levels of Skp2 and p27. Thus, the strongest association7B). Thus, reduction of p27 does not functionally substitute for
loss of Apc; homozygous mutation of Apc is still required for with p27 levels in GI tumors was not with Skp2, but rather with
the primary genetic lesion driving tumor development. p27 levelstumor development, independent of p27 status.
were much lower in tumors with Apc mutations relative to tumors
with Smad3 mutations.Nuclear accumulation of -catenin in tumors
from Min/, but not Smad3 mutant mice
To further define the molecular differences in the Min/ and Discussion
Smad-3 tumors, we examined -catenin and cyclin D1 expres-
sion patterns. The Apc protein functions as part of a complex We used several carcinogen protocols and two tumor prone
mouse models to address the role of p27 in the natural historythat binds to -catenin, leading to its phosphorylation and
subsequent ubiquitin-mediated degradation (Polakis, 2000). of intestinal neoplasia. While p27 deficient mice do not sponta-
neously develop intestinal tumors, they show markedly in-Mutations in Apc, such as those that occur in sporadic colorectal
cancers, disrupt the Apc:-catenin interaction, leading to creased predisposition to adenoma and adenocarcinoma devel-
opment in the small intestine and colon in response to four-catenin stabilization and its nuclear accumulation. Nuclear
-catenin, in turn, leads to activation of the Tcf/Lef-1 transcrip- diverse carcinogens: ENU, -radiation (Fero et al., 1998), DMBA
(Philipp et al., 1999), and DMH (this study). These agents pro-tion factors and induction of target genes such as cyclin D1
and myc. This pathway is clearly important in oncogenesis, as duce a variety of genetic lesions that likely result in cancer-
initiating mutations in a variety of oncogenes or tumor suppres-mutations in -catenin are detected in both human and murine
tumors, resulting in its stabilization and nuclear accumulation sor genes. The apparent requirement for carcinogen treatment
suggests that tumor suppression by p27 may be contingent on(Polakis, 2000). Tissue sections from DMH, Min/, and
Smad3/ induced tumors were stained for -catenin and ex- mutational activation in one or more oncogenic pathways. To
determine if there was specificity to the oncogenic pathway thatamined for -catenin localization. In normal GI, diffuse cyto-
plasmic -catenin staining was seen in intestinal epithelial cells. p27 might interact with, we used two genetic models of GI
neoplasia. Reduction of p27 greatly accelerated the rate of de-A similar pattern of -catenin staining was seen in all tumors
from Smad3 mutant mice (n  11) (Figure 5G). In contrast, all velopment of intestinal tumors with preexisting mutations in
Apc, but showed little or no effect in tumors with Smad3 muta-tumors examined from Min/ mice (n  5) displayed prominent
nuclear -catenin staining (Figure 5F), consistent with mutation tions. Thus, tumor suppression by p27 is not universal, but is
contingent on the specific genetic pathway altered in the tumorof Apc in these tumors. DMH-induced tumors displayed both
cytoplasmic and nuclear -catenin staining (Figure 5E). Thus, cells.
in DMH-induced and Min/ GI tumors, nuclear accumulation
of -catenin is a prominent feature, while in Smad-3 tumors, Pathways
p27 protein levels were reduced in a significant fraction of ade-nuclear -catenin is not observed. This result confirms that
different molecular pathways drive tumorigenesis in the Min/ nomas from Min/ mice and germline reduction of p27 greatly
accelerated the rate of development of tumors from Min/mice.compared to the Smad-3 mutant mice. Cyclin D1 has been
identified as one of many-catenin/Tcf/Lef1-target genes (Tetsu This indicates that p27 is inhibitory, and that there is strong
selective pressure to reduce p27 expression in mutant Apc-and McCormick, 1999), and its expression is increased in some
colon tumors. Relative to normal colonic tissue, cyclin D1 ex- driven tumorigenesis. What is the basis of the synergism be-
tween p27 and Apc? p27 binds to cyclin E/cdk2 complexespression was increased in adenomas from both Min/ and
Smad3/ mice (Figure 6C). This indicates that cyclin D1 can and inhibits cdk2 activity which can block cell cycle progression.
The increased proliferation seen in p27 deficient tumors frombe upregulated in tumors, independent of -catenin activation.
Min/ mice indicates that tumor development driven by muta-
tion in Apc is likely limited by cdk2 activity, and this is relievedExpression of Skp2/p45 is increased in GI tumors
p27 is regulated at several levels, including transcription, trans- by reduction of p27. Mutation in Apc contributes to tumor devel-
opment in at least two ways. The Apc protein is a componentlation, and protein stability (Philipp-Staheli et al., 2001). How-
ever, the basis for the variation in p27 expression seen between of the Wnt signaling pathway and normally functions to target
-catenin for degradation. Mutational inactivation of Apc resultstumors is not understood, although where examined, posttrans-
lational control is cited (Loda et al., 1997; Chiarle et al., 2000). in accumulation of -catenin in the nucleus, leading to activation
of Tcf/Lef-1 transcription factors and expression of target genes,Skp2 is an F box adapter protein that targets p27 for ubiquitin-
mediated degradation (Carrano et al., 1999). To determine if including cyclin D1 and c-myc (He et al., 1998; Shtutman et al.,
1999; Tetsu and McCormick, 1999). Both -catenin and cyclinp27 abundance correlated with Skp2 expression, we measured
Skp2 levels in tumors from the three models. Relative to normal D1 levels were increased in Min/ tumors. However, the fact
that cyclin D1 was also increased in Smad3 mutant tumors, yetcolon tissue, Skp2 was markedly increased in all GI tumors
examined from DMH treated mice (Figure 6B). Immunoblots reduction of p27 did not cooperate with this model, suggests
that the synergy between p27 and the Apc/-catenin pathwaywith nuclear proteins Sin3A and Max confirmed that cytoplasmic
fractions were not contaminated by nuclear proteins (Figure 6A is independent of cyclin D1 levels.
Apc also appears to contribute to tumorigenesis via an effectand data not shown). However, there was no clear association
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on chromosomal instability. Loss of Apc was recently shown Moreover, this effect was p27 gene dosage dependent. This is
consistent with the known function of p27 as a Cdk inhibitorto disrupt the interactions between the kinetochores and spindle
microtubules leading to chromosomal instability (Kaplan et al., and indicates that one mechanism of tumor suppression by p27
is to control tumor cell proliferation. Difficulty in detecting this2001; Fodde et al., 2001). Although we did not observe LOH of
p27 in tumors from Min/ p27/ mice, we did observed LOH link in human solid tumors could be due to imprecise measure-
ment of p27 expression through the use of immunohistochemis-of Apc in tumors from Min/ p27/, p27/, and p27 wild-
type mice. This indicates that complete loss of Apc was still try, the broad cell cycle distribution of Ki-67 expression as a
proliferation marker, or considerable genetic and phenotypicrequired for tumorigenesis regardless of p27 levels, and that
loss of p27 did not functionally substitute for loss of Apc. It is heterogeneity between tumors. In addition, p27 appears to play
additional roles in tumor suppression, beyond control of prolifer-possible that p27 deficiency accelerates genome instability in
Apc mutant tumors, although the effect of p27 on proliferation ation.
In addition to increasing tumor proliferation and growth,seems the most likely explanation for the observed synergistic
interaction between Apc and p27. reduction of p27 also resulted in an increase in malignant pro-
gression of tumors. A greater percentage of colon tumors fromThe contrast in frequency of LOH between p27 (0/23 tumors)
and Apc (23/23 tumors) within the same tumors highlights the DMH-treated p27 deficient mice were adenocarcinomas, with
features that included complete invasion through the muscularisdifference in gene dosage sensitivity between these two tumor
suppressor genes. Loss of one allele of p27 is sufficient to into the serosal space, and lymphatic vessel penetration. These
more aggressive phenotypes were not observed in tumors fromconfer a strong tumor growth phenotype, whereas loss of both
Apc alleles appears to be required for tumor development. p27 wild-type littermates. This suggests that an additional tumor
suppressing function(s) of p27 may be to control tumor cellThese two genes, at least in this context, appear to represent
two extremes of what is likely a continuum of dosage sensitivity differentiation, migration, and/or invasion. p27 has been shown
to induce differentiation of several cell types, including intestinalof tumor suppressor genes, ranging from haploinsufficient to
recessive. epithelial cells and colon carcinoma cells (Quaroni et al., 2000;
Baldassarre et al., 1999; Yamamoto et al., 1999; Hauser etSmad3 is an intracellular mediator of TGF- function and
acts as a nuclear transcriptional activator (Massague, 1998). al., 1997), and cells lacking p27 show impaired differentiation
(Casaccia-Bonnefil et al., 1997; de Koning et al., 2000; ZhangCells lacking Smad3 are deficient in TGF--mediated migration
and growth arrest responses (Ashcroft et al., 1999; Datto et al., et al., 1998). p27 is also implicated in cell adhesion, in that
p27 is upregulated when cells are grown in suspension or in1999). p27 was initially discovered in complexes with cyclin
E/cdk2 and cyclin D2/cdk4 in TGF- arrested Mv1Lu mink epi- response to E-cadherin or N-cadherin-mediated growth sup-
pression (St. Croix et al., 1996, 1998; Fang et al., 1996; Leven-thelial cells, implicating p27 in proliferation arrest signaling from
TGF- (Polyak et al., 1994a). However, subsequent studies berg et al., 1999). These attributes of p27 may have contributed
to the loss of differentiation and enhanced progression seen inshowed that cells lacking p27 still respond to growth inhibition
by TGF- (Nakayama et al., 1996). Other cdk inhibitors such p27 deficient tumors. p27 deficiency may confer the ability to
proliferate in the absence of proper extracellular matrix signalingas p15 and p21 are induced by TGF- and contribute to the
proliferation arrest of TGF- treated cells (Reynisdottir et al., that would occur as tumor cells invade through the basement
membrane or within lymphatic vessels, and hence facilitate cell1995; Hannon and Beach, 1994). TGF- signaling is inhibitory
to GI tumor development, as both TGF and Smad3 deficient survival and clonal expansion during metastatic spread.
Enhanced malignant progression was also observed inmice spontaneously develop GI neoplasms. In contrast to what
was observed in the Min/ model, p27 expression was not chemically induced skin tumors from p27 deficient mice (Philipp
et al., 1999) and is of considerable interest, given the correlationreduced and germline reduction of p27 had no apparent effect
on tumor growth in Smad3 mutant mice. This suggests that p27 between reduced p27 expression and increased tumor grade
and metastasis seen in human colorectal, gastric, and otheris not inhibitory, and there is little selective pressure to reduce
p27 expression in tumors with mutations in Smad3. This also cancers. Mortality from colorectal cancer is typically due to
extensive metastatic spread of the primary tumor to distal sites.indicates that p27 expression in GI tumors does not require
active TGF- signaling. The synthetic lethality observed in The association of reduced p27 expression in tumors with poor
patient survival may be due to a role of p27 in regulating meta-Smad3/p27 compound null mice formally demonstrates that
p27 is not solely regulated by Smad3 and that these proteins static spread of the tumor. The p27 deficient mouse model
should prove useful to further test this idea.lie on distinct pathways.
The observation that p27 shows pathway-dependent tumor
suppression may also have clinical implications. Although it isMechanisms
well established that p27 expression levels in human tumorsThe cellular mechanism for tumor suppression by p27 has not
correlate with patient survival, this correlation is imperfect. Therebeen established. Early reports on human solid tumors did not
may be a subset of tumors with defined genetic alterations thatdetect consistent associations between p27 levels and prolifera-
progress independent of p27 expression levels. Stratification oftion, as measured by proliferation markers such as Ki-67 stain-
tumors based on defined genetic alterations, in combinationing (Porter et al., 1997; Catzavelos et al., 1997; Loda et al.,
with p27 staining, may further improve prognostic sensitivity.1997; Esposito et al., 1997). However, some tumor types, such
as lymphomas, show an inverse correlation between p27 stain-
Experimental proceduresing and proliferative fraction (Sanchez-Beato et al., 1997; Quin-
tanilla-Martinez et al., 1998). Here, we show in two separate Mice
mouse models, using both mitotic counts and BrdU labeling, Inbred 129/Sv p27 deficient mice were obtained from J. Roberts and geno-
typed as described (Fero et al., 1996). The p27 knockout allele was back-that p27 deficiency resulted in increased tumor cell proliferation.
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crossed to the NIH strain for seven generations. 129/Sv p27/ mice were and normal tissues were minced with a razor blade and dissolved in buffer
A (Schreiber et al., 1989) and further homogenized for 1 min on ice (PowerGencrossed to NIH p27/mice to generate the F1 littermates used for carcino-
gen treatment. Mice were injected with 1,2-dimethylhydrazine (DMH) (15 mg 125, Fisher Scientific). Buffers A and C both contained 1 mM DTT, 0.4
mg/ml Pefablock, 25 mg/ml Aprotinin, 10 mg/ml Pepstatin, and 10 mg/mlper kg body weight, s.c.) once weekly for 12 weeks starting at 8 weeks of
age. DMH was dissolved in 0.001 M EDTA and adjusted to pH 6.5 using 8 Leupeptin (Boehringer Mannheim) to inhibit proteases, and in addition, buffer
C contained 25% glycerol. Protein concentrations were standardized usingN NaOH. Following the last treatment, mice were observed as described
below. the Bradford assay (BioRad) and equal loading was confirmed by Ponceau
S staining of PVDF membranes after electroblotting (BioRad). The antibodiesC57BL/6J ApcMin/ mice were obtained from Jackson Laboratory and
genotyped as described (Dietrich et al., 1993). The p27 knockout allele, used for Western blotting were: rabbit polyclonal antibodies from Santa Cruz
Biotechnology (Santa Cruz, CA) against p27 (sc-528), cyclin D1 (sc-753),which was originally on a mixed 129/Sv x C57BL/6 genetic background,
was backcrossed 14 times onto the C57BL/6 strain. As the Mom1 locus p45Skp2 (sc-7164), and Sin3A (sc-994) for cellular fractionation and loading
(Modifier of Min-1) on Chromosome 4 has a strong influence on the severity control. Anti-	-tubulin (clone B-5-1-2, Sigma) and anti-max antibodies (gen-
of the Min phenotype, we verified that the C57BL/6 p27 deficient mice erous gift of Dr. R. Eisenmann) served as additional controls for the complete-
indeed carried the C57BL/6 Mom1 allele (e.g., Mom1S/S) by PCR (Gould et ness of cellular fractionation. Blots were developed using chemilumines-
al., 1996). C57BL/6 Min/ mice were crossed to C57BL/6 p27/ mice cence protein detection kits for alkaline phosphatase (Tropix, Bedford, MA)
to generate Min/ p27/ which were intercrossed to generate Min/ or horseradish peroxidase (Pierce, Rockford, IL). Densitometric analysis of
littermates of all three p27 genotypes and observed as described below. Western blots was performed using ImageQuant software for Macintosh,
129/Sv Smad3/ mice were obtained from J. Graff and genotyped version 1.2.
as described (Zhu et al., 1998). The p27 knockout allele, which was originally
on a mixed 129/Sv x C57BL/6 genetic background, was backcrossed 14 Tumor DNA isolation and LOH analysis
times onto the 129/Sv strain and genotyped as described (Fero et al., 1998). DNA was extracted from frozen tumors using BioRad InstaGene Matrix.
129/Sv Smad3/ mice were crossed to 129/Sv p27/ mice to generate 10–15 mg of tumor tissue was digested in 100 
l volume with 1 mg/ml
Smad3/ p27/mice. These were intercrossed to generate Smad3/ Proteinase K over night at 37C followed by deactivation of Proteinase K at
p27/, Smad3/ p27/, and Smad3/ p27/ mice. However, 95C. The supernatant was used as a DNA template for the following two
only 3 out of 219 total offspring were of Smad3/ p27/ genotype, and PCR protocols. Retention of the remaining p27 allele in tumor tissue from
these did not live past 30 days of age. p27/ mice was analyzed using primers F (5 GAGCAGACGCCCAAGA
All mice were observed daily and sacrificed when moribund, which AGC 3), R (5 TGGAACCCTGTGCCATCTCTAT 3), and N (5CCTTCTATGG
included the following criteria: excessive loss of weight, abdominal swelling, CCTTCTTGACG 3). Tumor samples were amplified in a 25 
l reaction
rectal prolapse or bleeding, or anemia. Morbidity was scored as tumor- containing 500 ng of DNA, 2.5 
l of 10 PCR buffer, 2.7 mM MgCl2, 0.5
related if tumors resulted in intestinal obstruction or hemorrhaging, or mM dNTP, 0.1 mM of each of the three primers, F, R, and N, and 1 unit of
were1 cm3 . The entire small intestine, cecum, and colon was cut longitudi- Taq polymerase at the following conditions: first cycle 94C for 3 min; 40
nally and fixed on a bibulous paper. Intestinal tumors were enumerated using cycles 93C for 45 s, 55C for 60 s, 65C for 90 s; last cycle 65C for
a dissecting microscope. 10 min. Samples were run on a 1% agarose gel stained with ethidium
bromide.
Histopathogy and immunohistochemistry Loss of the wild-type Apc allele was analyzed using primers F
Sections of tumors were removed and flash-frozen in liquid nitrogen or fixed (5TCTCGTTCTGAGAAAGA-CAGAAGCT3) and R (5GATACTTCTTCCAAA
in 10% neutral buffered formalin for 4–6 hr and embedded in paraffin. After GCTTTGGCTAT 3) designed to introduce a HindIII restriction site without
high temperature antigen retrieval in 10 mM citrate buffer (pH 6.0), 5 mm altering the Apc point mutation at nucleotide position 2,549. Tumor DNA
sections were stained for p27 (mouse monoclonal antibody, Neomarkers, was amplified in a 25 
l reaction containing 100 ng of DNA, 2.5 
l of 10
Fremont, CA) for 1 hr, for -catenin (rabbit polyclonal antibody, Neomarkers, PCR buffer (500 mM KCl, 100 mM Tris, and 1% TritonX-100), 2.5 mM MgCl2,
Fremont, CA) for 1 hr, or for Ki67 (mouse monoclonal antibody, Novocastra 0.5 mM dNTP, 0.1 mM primers, and 1 unit of Taq polymerase. Samples
Laboratories Ltd., Newcastle upon Tyne, UK) for 1 hr. Standard avidin- were amplified using the following conditions: first cycle 94C for 3 min;
biotin peroxidase complex (ABC) techniques were used for primary antibody 40 cycles 93C for 30 s, 55C for 45 s, 65C for 1 min; last cycle 65C
detection (biotinylated goat anti-rabbit antibody, Vector Labs Inc., Burlin- for 10 min. 10 
l of postamplification samples were digested with HindIII
game, CA; streptavidin ABC, DAKO Corp., Carpinteria, CA). The slides were (10 units) overnight and run on a agarose gel (2% agarose/3% NuSieve)
developed in DAB/NiCl, then counterstained with methyl green. Controls stained with ethidium bromide.
included: no primary antibody and /or normal rabbit serum, and tissues from
p27 null mice. p27 and Ki67 staining were performed on serial sections. Statistical methods
Kaplan-Meier survival curves were used to display the time to tumor morbid-
Kinetic analysis of tumor cells ity or mortality. Corresponding two-sample logrank statistics were used to
Mice were injected with BrdU (1 mg/10 g body wt, i.p.) (Sigma) and sacrificed test for rate differences between genotype groups. Brookmeyer-Crowley
1 hr later. For BrdU staining, 4 
m paraffin sections were deparaffinized and confidence limits (Brookmeyer and Crowley, 1982) accompany estimates of
rehydrated. The sections were denatured with 2N HCl and treated with 0.1% median latency time to tumor morbidity or mortality. Two sample t tests for
trypsin (Sigma). Sections were then stained with a mouse monoclonal anti- samples with unequal variance were used for comparison of mean tumor
BrdU (DAKO) antibody followed by an anti-mouse IgG1 horseradish peroxi- numbers in Min/ mice. Logistic regression-based estimates, confidence
dase-linked antibody (Southern Biotechnologies). Sections were developed intervals, and hypothesis tests were used to display and compare the propor-
with DAB/NiC (Sigma) and counterstained with methyl green. BrdU-labeled tion of GI tumors with minimum specified diameter at selected follow-up
cells were counted at 400 magnification and expressed as positive cells times. The robust sandwich variance estimator (Huber, 1967) was used in
per crypt for normal GI or per 400 powerfield for tumors. Alternatively, these models to account for the nonindependence of tumor size observations
mitotic figures were counted in H&E stained sections of intestinal adenomas. from the same mouse. Exact binomial confidence limits were alternatively
Proliferation in DMH treated colon adenomas was established by counting used where the observed group proportion was zero, and for lower GI tumor
50–100 400 powerfields per genotype. One to two adenomas per mouse observations at 9 weeks of age due to small numbers. Fisher’s exact test
and 6–12 mice per genotype were evaluated. For Min/ mice, a total of 10 was used for comparison involving these groups. 95% confidence limits
powerfields were counted at 400 magnification in the colon and in three and p values are 2-sided.
distinct sections of the small intestine. At least 10 adenomas per mouse
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